Introduction
Cell cycle control is a highly coordinated process mediated by a diversity of genes and proteins. Cyclin-dependent kinases (CDKs) play a pivotal role in regulating the initiation and transition of cell cycle phases by inactivating phosphorylation of the retinoblastoma (RB) family of proteins, which leads to activation of the E2F transcription factors [1] . The E2F transcription factors cooperating with DP1/2 to sequentially transactivate the genes required for each phase of cell cycle progression [2] . While CDKs are positively regulated by several types of cyclins, their negative regulation is mediated by the CDK inhibitors (CDKIs), which are divided into two classes; the INK4 and CIP/KIP families based on their CDK inhibition spectrum [3] . Given the fundamental functions of the CDK/RB/E2F pathway in cell cycle control, deregulation of the components in this pathway, including genetic/epigenetic alterations, over-expression and post-translational aberrations, is a critical step in multistage carcinogenesis.
An INK4 family CDKI, CDKN2A (p16), binds to and inactivates CDK4 and CDK6 by inhibiting the association between these CDKs and D-type cyclins. The p16-mediated inhibition of D-type cyclins controls early G1 cell cycle progression [4] . Although other INK4 family proteins such as p15 (CDKN2B) and p18 (CDKN2C) show similar biological features in vitro, the frequency of deregulation of p16 in tumors is significantly higher [5] . A 5′-CpG island in the promoter region of the p16 gene is hypermethylated in various types of cancers including non-small cell lung cancer (NSCLC), breast cancer and hepatocarcinoma (HCC) [6] . The status of hypermethylation correlates with the p16 protein level when measured by immunohistochemistry in clinical samples. For example, in one study of NSCLC, ∼26% of 27 tumor samples examined showed hypermethylation in the promoter region of p16, leading to the downregulation of p16 mRNA expression [7] . The observation of mutual inactivation of p16 and RB in NSCLC and SCLC also points to an important role for p16 in carcinogenesis as a tumor suppressor gene [8] .
CDKN1B (p27) is a CIP/KIP family CDKI that binds to and regulates CDK2, 4 and 6. Upon UV irradiation or cell contact inhibition, the activated p27 inhibits D-type cyclins and CDKs, which arrests the cell cycle at the G1 phase. p27 reduction is also required for completion of the G1 phase and initiation of the S phase by sequential activation of E-type and A-type cyclin and CDK2 complexes. The activated CDK2 up-regulates transcription of genes which participate in DNA synthesis and subsequent processes that occur at S phase [9] . With respect to the association between p27 deregulation and cancer, p27 is frequently inactivated in various types of cancers, which implies a tumor suppressive function of the protein similar to p16. Unlike classical tumor suppressors such as p53 (TP53) and RB (RB1), genetic deletions or mutations of p27 are not frequently observed. However, multiple reports have demonstrated that the protein expression level of p27 is decreased or silenced in various types of cancers such as breast, colon, and lung cancer [10] . The mechanism of the decreased expression of p27 has also been investigated. The up-regulation of SKP2, which is the ubiquitin ligase E3 of p27, is one of the causative events of the decrease in p27 protein [11] . Despite detailed analysis of p27 from the perspective of its inhibition spectrum of CDKs and its post-translational regulation, p27-regulatory mRNA gene expression as an end point of the p27/CDK/RB pathway remains elusive.
Although both p27 and p16 are inactivated at high frequency in many types of cancers, and possess a common function involving down-regulation of E2F regulatory genes via activation of RB proteins, the impact of their expression levels on clinical prognosis differs [12] . p27 is widely regarded as an adverse prognostic indicator in a number of tumor types, while p16 seems not to be an independent risk factor. In a colon cancer study, the survival rate was poorer in p27-negative tumors (median, 69 months) compared with p27 positive tumors (median, 151 months), and p27 was an independent prognostic marker [13] . In HCC, p27 acts as an independent predictor of HCC recurrence among several cell cycle regulators such as RB, p21 (CDKN1A), cyclin D1 and p16 [14] . Breast cancer is one of the most extensively studied tumor types with respect to the relationship between p27 and prognosis. Reduced overall survival correlated significantly with down-regulation of p27 expression in a retrospective analysis with more than 2000 samples [15] . In contrast, limited studies have shown the implications of p16 as a prognostic predictor, although both p16 and p27 exhibit an inhibitory effect on cell cycle progression via reducing E2F target genes. The molecular mechanism by which p27 plays a distinct role from p16 as a prognostic factor remains elusive.
To date, a number of DNA microarray studies have clearly shown their effectiveness in analyzing the molecular mechanisms at work in the CDK/RB/E2F pathway. mRNA expression profiling of cultured cells with over-expression of exogenous E2F enabled identification of novel E2F regulatory genes [16] [17] [18] [19] [20] [21] [22] [23] . Microarray analysis of U2OS cells with ectopic p16 expression or constitutively active RB expression has also led to the identification of p16/RB regulatory genes [24] . We have also performed molecular profiling of RB positive and negative matched pair cell lines, which resulted in the identification of ECT2 as a novel E2F regulatory gene [25] . These studies have demonstrated that global expression profiling is a powerful approach to decipher the CDK/RB/ E2F pathway.
In the present study, we performed microarray analysis of cultured cells over-expressing either p27 or p16 in order to investigate their common and distinct features. While E2F-target genes were enriched among the genes that were commonly changed by both CDKIs, significant enrichment of NF-Y-target genes was unexpectedly observed in the gene set specifically down-regulated by p27 expression. The prediction of prognosis using the NF-Y-target genes indicated that samples with up-regulated expression of the NF-Ytarget genes regulated by p27 showed poor prognosis in multiple cancers, which could explain the molecular mechanism underlying the distinct features of p27 and p16 as prognostic factors.
Results

Identification of the genes commonly regulated by both p16 and p27 induction
To identify p16 and p27 target genes by microarray analysis, human colorectal HCT116 cells were infected with adenovirus expression vectors containing p16, p27, or the control lacZ gene at a titer of 200 multiplicity of infection (moi). Before analysis, expression levels of the CDK inhibitors in the cells were confirmed with RT-PCR and Western blotting. Similar expression levels were observed for both mRNA and protein of p16 and p27 ( Fig. 1a and b) . Cell growth was arrested in both cells expressing p16 and p27. Cell cycle distribution and subG1 fraction was also observed (Fig. 1c) . As a significant increase in subG1 fraction was observed in cells expressing the CDK inhibitors, exogenously introduced p16 and p27 were confirmed to be functional in HCT116 cells.
To elucidate the common and distinctive molecular functions between p16 and p27, we carried out mRNA expression profiling of the HCT116 cells over-expressing either p16 or p27 protein. At 24, 36, 48 and 72 h post infection, RNA was extracted from the cells and subjected to mRNA expression profiling using the Affymetrix oligonucleotide microarray, human GeneChip HG-U95Av2.
To determine the conserved similar roles between p16 and p27, we selected genes whose expression was commonly up-or downregulated by both of the CDKIs. By comparing the expression profiles of the HCT116 cells over-expressing p16 or p27 and control LacZ, we extracted the genes which showed significant (P ≤ 1.0 × 10
expression changes in at least one of the time points (24, 36, 48 or 72 h) in both of the cells over-expressing p16 and p27. Elimination of genes with a small range of expression change was also performed as described in Materials and methods. Using the described criteria, 62 and 5 probes were extracted as down-and up-regulated genes respectively. In Fig. 2 , shows the hierarchical clustering of the selected genes, verifying the conserved regulation of the clustered genes by both of the CDKIs. To examine the relationship between the selected genes and cell cycle phases, the genes known to be tightly regulated at each phase of S, G1/S, G2, G2/M and M/G1 were annotated for the commonly regulated genes ( Fig. 2 right panel) . The annotation was based on previous studies conducted by Whitfield et al. which comprehensively investigated cell cycle related genes by performing mRNA expression profiling of HeLa cells in which the cell cycles had been synchronized [26] . As the figure shows, time course-dependent cell cycle related gene expression changes were induced by the CDKIs. Down-regulation of G1/S related genes was observed at 24 h followed by down-regulation of the G2/M related genes at 36 to 48 h, which confirmed that both CDKIs prevent cell cycle progression via the CDK/ RB/E2F pathway.
Identification of the genes whose expression is specifically regulated by p16 or p27
In addition to the common features of the two inhibitors, distinct functions of p16 and p27 have also been reported, and include the example of different inhibitory partners of CDKs by the CDKIs. Next, to investigate the specific roles of each of the two CDKIs, we selected genes whose expression was selectively changed by the exogenous over-expression of each CDK inhibitor. The specifically regulated genes were selected based on the following criteria: 1, genes which showed more than 2.5-fold expression changes with statistical significance (P ≤ 1.0 × 10 − 5 ) in at least one of the time points (24, 36, 48 or 72 h) in p27 over-expressed cell lines; and 2, genes which did not show significant expression changes at any of the time points by the over-expression of p16. With respect to genes specifically regulated by p16, for the most part the same criteria were utilized but a fold-change threshold of 1.5 was applied. With the cut-off values, 53 probes were shown to be specific p27 regulatory genes, of which 49 and 4 probes were decreased and increased, respectively, by the overexpression of p27. Regarding p16 specific genes, 8 and 4 probes were identified to be down-and up-regulated genes, respectively. Fig. 3 shows the hierarchical clustering of the genes specifically regulated by p27 ( Fig. 3a) and p16 ( Fig. 3b ) with annotation of cell cycle phases as defined in the analysis of commonly regulated genes. Different from the result of commonly regulated genes, the G2/M related genes were enriched among the p27 regulatory genes, suggesting additional functions for p27 in the coordination of G2/M cell cycle progression compared with p16. In contrast, no significant relationship to any cell cycle phase was observed among the p16 regulatory genes.
In silico identification of the transcription factors participating in the networks of p16 and p27
The downstream regulatory genes induced by p16 and p27 that were identified in the current molecular profiling (Fig. 3 ) differed markedly, which infers that p27 and p16 transduce signals to distinct downstream transcription factors. Next, in order to identify the transcription factors responsible for the differences in the mRNA expression profiling between the p16 or p27 inductions, we searched by in silico analysis for transcription factors that bind to the promoter region of the commonly or specifically regulated genes. We analyzed the promoter regions of six groups of genes: commonly up-or downregulated by both p16 and p27, specifically up-or down-regulated by p27, and specifically up-or down-regulated by p16. The in silico identification of transcription factors was performed using the TRANSFAC database (release 11.3, November 2007) [27] and overabundance of the identified binding sites among each gene set was evaluated based on hypergeometric distribution. Consistent with previous reports, E2F family transcription factor binding sites were significantly overabundant within the genes commonly downregulated in p16 and p27 over-expressed cells (Table 1a) . In contrast, NF-Y transcription factor binding sites were significantly overabundant among the genes specifically down-regulated by p27 but not by p16 (Table 1b, Fig. 4a ), indicating that the majority of the p27 regulatory genes were down-regulated by an NF-Y transcription factor downstream of the p27/CDK cascade. In the analysis of the promoter regions of the other gene sets, no significant overabundance of any of the specific transcription factor binding sites was observed (data not shown). The genes specifically down-regulated by p27 induction that contain an NF-Y binding motif in their promoter regions are listed in Table 2 , and an enrichment test for the genes was performed by gene ontology biological process annotation (Fig. 4b) . The results demonstrated that statistically significant overabundance of mitosis-related genes was included in the NF-Y target genes specifically down- The listed transcription factor binding motifs of TRANSFAC were enriched among the genes down-regulated in both p16 and p27 over-expressed cell lines. Transcription factor binding sequence motifs for each TRANSFAC motif ID are shown in Supplemental Fig. 1 . List of the transcription factor binding motifs enriched among the genes specifically down-regulated in p27 over-expressed cell lines but not in p16 over-expressed lines.
Enrichment P values were calculated using the hypergeometric distribution. regulated by p27 such as CDC2, MCM7 Aurora-A, TPX2, PLK1, CENPF, TOP2A, BLM, SPC25, and PTMA (P ≤ 1.0 × 10 − 12 ) (Fig. 4b, Table 2 ), which are known to regulate chromosome condensation, centrosome regulation or sister chromatid separation [28] . This further supports the idea that p27 negatively regulates a diverse array of mitotic events through the NF-Y transcription factor. Activation NF-YA (NFYA), a regulatory subunit of NF-Y, was experimentally measured in HCT116 cells followed by p16 or p27 induction. Nuclear extracts from the HCT116 cells at 0, 24, 48 and 72 h post CDK inhibitor induction was used to quantify the binding ability of NF-YA to the oligonucleotide harboring the NF-YA consensus binding site (5′-CCAAT-3′). While p16 induction did not change NF-YA activity, p27 induction significantly reduced the activity to 49% compared with the control at 72 h post infection (Fig. 5 ).
Expression levels of the genes specifically regulated by p27 show significant correlation with tumor prognosis One of the most remarkable clinical differences between p16 and p27 is the association of tumor prognosis with the expression level of the each CDK inhibitor. Multiple studies have suggested that reduced p27 protein levels are associated with poor prognosis [10] ; although the information on the association with p16 is limited. We hypothesized that the difference in the transcriptional control downstream of the two CDKIs, in particular the NF-Y-target genes in the p27 gene signature, would be one of the determinants responsible for the prognosis difference between the two CDKIs. To examine this hypothesis, we checked the correlation between the expression profiles of the 17 genes in Table 2 and tumor prognoses. We collected publicly available microarray data of four types of tumors with patient survival information (Breast, van de Vijver et al. [29] ; lung, Bhattacharjee et al. [30] ; multiple myeloma, Carrasco et al. [31, 32] ; Renal, Yang et al. [33] ), normalized the data (as detailed in Materials and methods), and calculated the average expression values of the genes in Table 2 . Based on the calculated values, patients were divided into two groups. The poor prognosis group (mean expression levels ≥0) and the good prognosis group (mean expressions b0). For each tumor type, overall survival probabilities between the two groups were compared using Kaplan-Meier analysis and the log-rank test and it was found that the tumor prognoses were significantly different between the two groups in all the four tumors (Fig. 6) . In breast cancer, for instance, in which 167 and 128 patients were classified as having good and poor prognosis respectively, the survival probabilities were significantly different between the two groups, (P = 2.3 × 10 − 10 ) (Fig. 6a) . Similarly, the expression levels of the NF-Y-target genes in the p27 gene signature were associated with good and poor prognosis in the lung cancer, multiple myeloma and renal cancer patients. On the other hand, when tumors were divided by the expression levels of the genes specifically down-regulated by p16, significant differences were not observed between the two groups for any type of tumor (Table 3 ). When the prognosis was predicted by the genes down-regulated by p27, a prognosis difference was observed between the two groups, but with a lesser difference compared with that predicted by the NF-Y-target genes (Table 3) .
Discussion
This analysis of expression profiling has shown that E2F target genes were enriched in the commonly regulated genes by p16 and p27, providing confirmation of the function of CDKI in repressing E2F regulatory genes. While p16 exerts its inhibitory activity on cell cycle progression by binding to CDK4/6, p27 is known to form complexes with CDK2 in addition to CDK4/6. The inhibition of CDK2 or CDK4/6 prevents phosphorylation of RB as a conserved characteristic of all the CDKs, bestowing docking sites on E2F transcription factors that lead to down-regulation in their regulatory genes. Consistent with the present study, a number of reports have illustrated that overexpression of CDKIs down-regulates E2F regulatory genes such as CCNA2, CCNB1 and PCNA, although global expression profiling comparing p16 and p27 has not been reported [24, [34] [35] [36] [37] . Enrichment of the E2F regulatory genes in the common gene signature induced by p16 and p27 ensures that the experimental design and thresholds were reasonable in order to identify commonly and specifically regulated genes by p16 and p27.
The analysis of the p27 specific genes using the hypergeometric distribution test and the in silico promoter search suggested that the suppression of the NF-Y-target genes that coordinate G2/M cell cycle transition is a distinct feature of p27 compared with p16. p27 is well known to form complexes with CDK2 in addition to CDK4/6 in G1/S cell cycle transition. Previously, CDK2 has been reported to phosphorylate NF-Y transcription factor as one of the primary substrates in cancer cells in response to mitotic stimuli, which leads to an increase in its transactivation ability [38] . The importance of NF-Y in G2/M cell cycle transition under the control of CDK2 has been demonstrated in both in vitro and in vivo studies [39] . Given the relationship between p27 and CDK2, and CDK2 and NF-Y, the novel finding in the present study that p27 over-expression down-regulates NF-Y-target genes might be explained by the following sequential events: p27 induction in HCT116 inactivates CDK2 kinase activity and the resulting hypophosphorylated NF-Y thus reduces expression of its target genes. As this mechanism is based on results obtained with HCT116 cells, its applicability to other cell lines is limited. Some genes included in Table 2 have already been reported to be regulated by p16 in U-2 OS cells [24] . Further studies are needed in other types of cell lines to confirm this mechanism. Moreover, further validation studies examining the regulation of the genes in Table 2 by NF-Y both in vitro and in vivo, in addition to the present in silico analysis, would strengthen our argument.
The expression of p27 is associated with poor prognosis in a variety of tumor types. In hormone receptor positive breast cancer, for instance, lower expression of p27 was correlated with both lower overall survival and lower disease free survival, while no prognostic association was observed for CyclinE which was examined as a downstream effecter for p27 [15] . Another study on lung cancer also showed that deregulated expression of p27 is a strong indicator for poor patient prognosis, in contrast to the finding that the p16 expression level did not exhibit any correlation with prognosis, highlighting the useful role of p27 to predict patient prognosis [40] . Despite the various reports indicating the role of the expression level of p27 as a prognostic factor, the molecular mechanism explaining why p27 expression determines the prognosis has remained unknown. The present study found that NF-Y-target genes specifically regulated by p27 correlated with poor prognosis in multiple tumors such as breast, lung, renal cancers and multiple myeloma. Although p27 controls the expression levels of both E2F-and NF-Ytarget genes downstream of the CDKI/CDK cascade, the expression changes in the genes regulated by the NF-Y transcription factor would associate with clinical prognosis. Indeed, many oncogenic proteins such as MELK, Aurora kinase, and TPX2 were included in the NF-Y-target genes ( Table 2 ) which are known to modulate a diverse range of phases of the G2/M cell cycle [41, 42] . The NF-Y-target genes may enhance cancer progression by accelerating G2/M phase cell cycle transition, leading to poor patient prognosis.
In summary, we have identified the specific role of p27 compared with p16 to regulate NF-Y-target genes as an end point in its downstream cascade. The common and specific functions predicted through the analysis of the expression profile are depicted in Fig. 7 . Moreover, the importance of the NF-Y-target genes regulated by p27 induction has been proposed by associating the NF-Y-target genes with patient prognosis in several types of tumors. This global expression analysis has provided some insights into the specific function of p27 and its relevance to cancer prognosis, and may explain how p27 is associated with prognosis in various types of cancer compared with p16, despite both CDKIs being aberrantly expressed in multiple tumors.
Materials and methods
Quantitative RT-PCR assay
Human colon carcinoma HCT116 cells were infected with p16-, p27-or lacZ-expressing adenovirus (200 moi). cDNA was synthesized Table 3 Correlation between expression levels of each signature and tumor prognosis.
Down-regulated only in p27
Down-regulated only in p16
Genes in This table shows the relationship between patient survival and the expression level of each set of genes. P values were calculated using the log-rank test, when breast, lung, multiple myeloma and renal cancer patients were classified into two groups based on the expression level of each set of genes. When patients were classified based on expression level of the genes in Table 2 , the patient survival rate showed the most significant difference for each tumor. Fig. 7 . Probable regulatory network of p16 and p27. E2F family transcription factor activity is inhibited by both p16 and p27 through the inhibition of CDK4 and CDK2. On the other hand, NF-Y activity is modulated by CDK2, and p27 affects on NF-Y transcriptional activity, whereas p16 does not. When we checked the correlation between the expression profile of the genes and tumor prognosis, the NF-Y regulatory genes showed the most significant correlations. NF-Y regulation through CDK2 may explain why decreased p27 levels are linked to poor outcome in several types of tumors.
from 1 μg total RNA using TaqMan reverse transcription reagents (#N8080234, Applied Biosystems). Quantitative real-time PCR was performed for human p16, p27 and β-actin in triplicate for cDNA samples in 96-well optical plates. Data were collected and analyzed using an ABI PRISM 7900 sequence detector system (Applied Biosystems). Commercially available pre-designed primers and probe for RT-PCR were used: p16 (Hs00233365_m1, Applied Biosystems); p27 (Hs00153277_m1, Applied Biosystems); β-actin (4310881E, Applied Biosystems).
Western blotting
HCT116 cells were infected with p16-, p27-or lacZ-expressing adenovirus. After 72 h infection, equal amounts of protein were extracted and resolved on NuPAGE 4-12% Bis-Tris polyacrylamide gels (Invitrogen, Carlsbad, CA) and then electrophoretically transferred onto PVDF membranes (Millipore, Billerica, MA). Membranes were incubated with anti-p16 (sc-1005, Santa Cruz Biotechnology, CA), anti-p27 (sc-1005, Santa Cruz Biotechnology) or anti-β actin (sc-1005, Santa Cruz Biotechnology) antibodies, followed by HRP-conjugated secondary antibody. Antibody binding was detected using the ECL system (GE Healthcare, Piscataway, NJ).
Flow cytometry
Using the treated HCT116 cells prepared as described for Western blotting, following 72 h infection, cells were stained using Cycle TEST™ PLUS DNA Reagent Kit (Becton Dickinson, Franklin Lakes, NJ) and analyzed by flow cytometry with FACSCalibur (BD Biosciences, CA).
Microarray analysis with Affymetrix GeneChips
Affymetrix human GeneChips HG-U95Av2 (Affymetrix, Santa Clara, CA) were used in all experiments. The samples for Affymetrix DNA microarray analysis were prepared as described by the manufacturer. An initial analysis of the data generated from the microarray images focused on simple determinations of fold changes within the comparisons of lacZ containing virus vector infected HCT116 cell samples versus p16 or p27 containing virus vector infected HCT116 cell samples, at each time point (24, 36, 48 and 72 h). Data analysis was performed using Resolver software (Rosetta Biosoft, Seattle, WA). In the Resolver system, intensity profiles were calculated with Affymetrix APT RMA algorithm. The intensity profiles generated were used to build ratios using Rosetta Resolver Ratio Builder for calculating the fold change and its P values for the differential expression between p16/p27-and lacZ-over-expressing cells. The criterion for a significant change in expression was P ≤ 0.00001. The P values were statistically significant (P ≤ 0.05) when multiplicity corrected P values were calculated with Benjamini-Hochberg FDR. To identify genes whose expression was regulated by both p16 and p27, we first extracted the genes which showed significant expression changes in at least one of the time points in both of the cells overexpressing p16 and p27. Next, to filter out genes with a small range of expression change, genes were eliminated if more than 1.5-fold and 2.5-fold changes were not observed in p16 and p27 over-expressed cell lines, respectively. The fold-change thresholds were determined based on the changes in expression of major E2F regulatory genes; as shown in Supplementary Fig. 2 , the average change in expression of the E2F regulatory genes induced by p16 and p27 were 1.6-and 2.2-fold at 24 h post infection, respectively. When genes were specifically regulated by p16 and not by p27, we selected the genes which showed more than 1.5-fold expression changes with statistical significance in at least one of the time points in p16 over-expressed cell lines but no significant expression change in any of the time points by the p27 over-expression. For the genes specifically regulated by p27, for the most part the same criteria were utilized, except that a 2.5-foldchange threshold was applied. To produce the hierarchical clustering of each gene set, MATLAB software (The Mathworks, Natick, MA) was used to perform the calculation and to display the results graphically. Cosine correlation was applied to calculate gene distances and a hierarchical tree was created based on average linkage. For all calculations the log ratio was used.
Transcription factor prediction
The transcription factor binding site matrices were obtained from version 11.3 of TRANSFAC® Professional [27] , and using only high quality matrices for the vertebrate group. To search for putative transcription factor binding sites in DNA sequences with these matrices, we used Match™ with a cut-off of minimizing false positive rate (minFP) [43] . The promoter region of each gene was generated through the following procedure. We obtained the "upstream1000. zip", "refMrna.zip" and "refSeqAli.txt.gz" files from the University of California Santa Cruz genome browser (http://genome.ucsc.edu, assembly released on March 2006, version hg18) [44] . Depending on the alignment information of each gene in refSeqAli.txt.gz, and using refMrna.zip and upstream1000.zip, we produced promoter sequences that included 1000 bp of upstream sequence from the start site of each Reference Sequence (RefSeq) [45] and the exon 1 sequences of each RefSeq. If the length of the exon 1 sequence was over 200 bp, we used only 200 bp of exon 1 and cut off the extra nucleotides. The correspondence of each gene on the GeneChip to the RefSeq ID was determined according to NetAffx [46] . The promoter sequences of 8321 genes could be specified among the 10500 genes on the GeneChip. To identify statistically overabundant transcription factors for the promoter region of the co-regulated group of genes, we calculated the P values using the hypergeometric distribution function:
where N is the total number of the genes in a given set of signatures, x is the number of genes that have a promoter sequence predicted to have a binding site for the transcription factor among the signature genes, K is the number of genes having promoter sequences which have binding motifs of the transcription factor, and M is the total number of genes in the control promoter sequences (in this study M was set to 8321).
Enrichment test
According to NetAffx and the BIOBASE's Proteome BioKnowledge Library (HumanPSD™) from Incyte Corporation (Incyte, Wilmington, DE) [47] , we annotated each gene with Gene Ontology (GO) biological process terms [48] . To determine whether the GO terms associated with particular biological processes were over-represented among the genes in each gene set, we calculated the P values using the hypergeometric distribution function. The function to calculate the P values was the same as function (1) , where N was the number of genes in a given set, x was the observed number of genes found in both a given set of genes and a given functional category, K was the number of the genes in a given functional category, and M was the total number of the genes represented on the microarray (in this study M was set to 8601).
NF-YA activity assay
HCT116 cells were infected with p16-, p27-or lacZ-expressing adenovirus. At 0, 24, 48 and 72 h post infection, nuclear extract from the HCT116 cells were recovered with Nuclear Extract Kit (Active Motif, CA). The NF-YA activity in the nuclear extracts were measured with TransAM NF-YA transcription factor assay kits (Active Motif). Briefly, 3 μg of nuclear extracts were incubated with the oligonucleotide containing the NF-YA consensus binding site which was immobilized on a 96-well plate. NY-FA antibody was added and incubated for 1 h followed by an additional 1-h incubation with antiIgG HRP conjugate. Then, the NF-FY activity was quantified by spectrophotometry.
Public microarray data for primary tumors
Four data sets were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov, GSE4452 for multiple myeloma [31, 32] and GSE2748 for renal cancer [33] ) and from the authors' individual web pages (Rosetta Inpharmatics web site: http://www. rii.com/publications/2002/nejm.html for breast cancer [29] and Broad Institute of MIT web sites: http://www.genome.wi.mit.edu/ cgi-bin/cancer/publications/pub_menu.cgi for lung cancer [30] ). These data sets included both single-channel Affymetrix (lung, multiple myeloma and renal) and dual-channel oligonucleotides (breast) array data. The dual-channel microarray data of breast cancer shows ratio values of each tumor versus pooled tumors for each gene. In contrast, the single-channel data shows intensity values of each tumor for each gene. In order to analyze these data in the same fashion, we preprocessed the intensity based microarray data and calculated the ratio expression values for each gene against the averaged intensity value of all tumors in each data set. The normalization step was as follows: signal intensities were log transformed, and average values were calculated for each gene with all tumor samples. By subtracting the averaged values from the intensities of each sample, the log ratio values were calculated. When log transformation was applied, we used log10 transformation for MAS5 based intensities and log2 transformation for RMA based intensities.
Correlation of the microarray data with tumor prognosis
All of the collected primary tumor datasets also have survival time parameters for the patients. To check the correlation between the expression profile of a given set of genes and tumor prognosis, the data was analyzed using Kaplan-Meier curves and the log-rank test. In each microarray dataset of a primary tumor, once a gene set was given, the average expression value of the genes was calculated for each tumor and the tumors were divided into two groups based on whether the value was positive or negative. After classifying the tumor samples, the log-rank test was applied to infer the statistical significance of differences in survival time between the two groups, and a Kaplan-Meier plot was also used to show the differences in survival. All the calculations were performed using MATLAB software (The Mathworks).
